Global Luteinizing Hormone Test Market Highlights 2022-2030
The global luteinizing hormone test market is estimated to grow with a high CAGR during the forecast period, i.e., 2022-2030. The increasing infertility rate globally, along with the growing investment in the innovation of technologically improved products are expected to fuel the development of the market. The growth of the market can also be attributed to factors, such as, the increasing awareness among the population towards gynaecological problems and the rising middle-class population in the emerging economies on a global level. According to the data collected from the World Health Organization (WHO), in 2020, approximately 48 million couples, and 186 million individuals across the globe live with infertility. Such increasing number of infertility rate has rapidly increased the requirement for luteinizing hormone test in the market. Moreover, the growing incidence rate of prostate cancer is another major factor coupled with raised chances of living of a person when treated with luteinizing hormone releasing hormone (LHRH) agonist therapy combined with surgery is expected to boost the market growth. Furthermore, the propelling demand for ovulation and fertility monitors in emerging economies is expected to develop remarkably in the upcoming years on account of the rising prevalence of PCOS, increasing infertility rates, obesity, growing fertility education, and easy availability of fertility monitors through online platforms, pharmacies, and offline stores, drugstores.
The global luteinizing hormone test market is segmented by disease indication into irregular menstrual cycle, infertility, PCOS, pituitary disorder, and others, out of which, the infertility segment is anticipate to garner a notable market share over the forecast period, owing to the increasing concerns regarding infertility among couples. According a report by the Centres for Disease Control and Prevention (CDC), 8.8% women between 15 to 49 years of age experience infertility in the U.S., as of 2017. Based on distribution channel, the market is segmented into hospitals, clinics, diagnostic centres, fertility centres, and others. Out of these, the fertility centres segment is estimated to hold the largest share in the market throughout the forecast period, on the back of growing concern and awareness for infertility among the couples and individuals across the developing and developed countries. CLICK TO DOWNLOAD SAMPLE REPORT
Major Macro-Economic Indicators Impacting the Market Growth
According to the statistics by the World Health Organization, the global per capita healthcare expenditure amounted to USD 1,064.741 in the year 2017. The worldwide healthcare expenditure per person grew from USD 864.313 in 2008 to USD 1,110.841 in 2018, where the U.S. is the top country that amounted to healthcare expenditure of USD 10, 623.85 per capita in 2018. As of 2018, the domestic general government healthcare spending in the U.S. was USD 5355.79, which grew from USD 3515.82 in 2008. These are some of the factors responsible for market growth over the past few years. Moreover, as per the projections by the Centers for Medicare & Medicaid Services (CMS), the estimated average annual percent change related to National Health Expenditures (NHE) in the U.S. was 5.2% in 2020 as compared to 2019 (4.5%). Furthermore, the National Health Expenditures are projected to reach USD 6,192.5 Billion in 2028, where the per capita expenditure is estimated to touch USD 17,611 in the same year. These are notable indicators that are anticipated to create lucrative business opportunities in upcoming years.
Global Luteinizing Hormone Test Market Regional Synopsis
Geographically, the market is segmented into North America, Latin America, Europe, Asia Pacific and the Middle East & Africa region. The market in the Asia Pacific is predicted to grow at the highest CAGR over the forecast period owing to the growing population, increasing awareness regarding infertility among the individuals in the region. The market in North America is anticipated to garner the largest share in terms of revenue, owing to the increasing incidence of infertility among the women aged between 15-44 years in the region. According to other report by the CDC, annually approximately 6.1 million women, that is 10% of the women in the U.S., face difficulty to conceive or staying pregnant. Such increasing issues during the reproductive age among the individuals and couples is further expected to drive the demand for luteinizing hormone test in the North American countries.
The global luteinizing hormone test market is further classified on the basis of region as follows:
- North America (U.S. & Canada) Market size, Y-O-Y growth & Opportunity Analysis
- Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market size, Y-O-Y growth & Opportunity Analysis
- Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC, Poland, Turkey, Russia, Rest of Europe) Market size, Y-O-Y growth & Opportunity Analysis
- Asia-Pacific (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market size, Y-O-Y growth & Opportunity Analysis
- Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market size, Y-O-Y growth & Opportunity Analysis
Market Segmentation
Our in-depth analysis of the global luteinizing hormone test market includes the following segments:
By Disease Indication
- Irregular Menstrual Cycle
- Infertility
- PCOS
- Pituitary Disorder
- Others
By End-User
- Men
- Women
By Distribution Channel
- Hospitals
- Clinics
- Diagnostic Centers
- Fertility Centers
- Others
Growth Drivers
- Rising Cases of Infertility
- Increasing in the Incidence of Male Hypogonadism
Challenges
- Strict Regulations on Test Quality by FDA
- Lack of Accuracy & Specificity
Top Featured Companies Dominating the Market
- Merck & Co.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Cigna Corporation
- Lee BioSolutions, Inc.
- Proov Inc.
- Swiss Precision Diagnostics GmbH
- Abbott Laboratories
- Quidel Corporation
- Geratherm Medical AG
- bioMérieux SA
- CIGA Healthcare Ltd
